Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-20 00:05 | 2025-05-15 | INSM | INSMED Inc | Flammer Martina M.D. | Officer | SELL | $65.79 | 11,724 | $771,276 | 84,797 |
| 2025-05-20 03:52 | 2025-05-16 | ACAD | Acadia Pharmaceuticals Inc. | Kihara James | Officer | SELL | $22.50 | 4,000 | $90,000 | 20,395 |
| 2025-05-20 03:50 | 2025-05-16 | ACAD | Acadia Pharmaceuticals Inc. | Schneyer Mark C. | Officer | SELL | $25.00 | 2,000 | $50,000 | 62,130 |
| 2025-05-20 00:20 | 2025-05-15 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | Officer | OPT+S | $46.13 | 2,812 | $129,717 | 103,901 |
| 2025-05-16 23:15 | 2025-05-15 | THAR | Canton Strategic Holdings, Inc. | Parikh Sanam | Director | BUY | $1.30 | 770 | $1,001 | 770 |
| 2025-05-16 23:30 | 2025-05-15 | NUVL | Nuvalent, Inc. | Porter James Richard | Director, Officer | OPT+S | $69.60 | 27,000 | $1,879,216 | 249,062 |
| 2025-05-17 01:00 | 2025-05-16 | LGVN | Longeveron Inc. | Hare Joshua | Director, Officer, 10% owner | SELL | $1.40 | 5,250 | $7,367 | 721,796 |
| 2025-05-17 00:23 | 2025-05-16 | ABEO | Abeona Therapeutics Inc. | Alvino Mark | Director | SELL | $5.68 | 8,000 | $45,440 | 92,435 |
| 2025-05-16 23:01 | 2025-05-14 | GYRE | GYRE THERAPEUTICS, INC. | Ma Songjiang | Director, Officer | SELL | $10.69 | 2,020 | $21,586 | 2,818,824 |
| 2025-05-16 23:23 | 2025-05-16 | CYTK | CYTOKINETICS INC | Blum Robert I | Director, Officer | SELL | $30.93 | 5,000 | $154,650 | 412,629 |
| 2025-05-16 23:57 | 2025-05-15 | ANIP | Ani Pharmaceuticals Inc. | Gutwerg Ori | Officer | SELL | $60.07 | 881 | $52,922 | 89,897 |
| 2025-05-16 18:28 | 2025-05-13 | LFCR | LIFECORE BIOMEDICAL, INC. DE | English Aron R. | 10% owner | SELL | $7.00 | 12,334 | $86,353 | 1,650,240 |
| 2025-05-16 01:48 | 2025-05-13 | APUS | Apimeds Pharmaceuticals US, Inc. | Kim Christopher | Director, Officer | BUY | $1.83 | 27,500 | $50,358 | 27,500 |
| 2025-05-15 23:17 | 2025-05-14 | LLY | ELI LILLY & Co | Yuffa Ilya | Officer | SELL | $749.24 | 1,250 | $936,550 | 27,510 |
| 2025-05-16 04:35 | 2025-05-13 | MNKD | MANNKIND CORP | Binder Steven B. | Director | SELL | $4.69 | 80,144 | $375,875 | 1,006,611 |
| 2025-05-15 23:27 | 2025-05-13 | ZLAB | Zai Lab Ltd | Du Ying | Director, Officer | OPT+S | $28.34 | 96,389 | $2,731,510 | 479,851 |
| 2025-05-16 02:01 | 2025-05-14 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | SELL | $15.29 | 11,366 | $173,774 | 106,669 |
| 2025-05-16 00:37 | 2025-05-13 | BGNE | BeOne Medicines Ltd. | Wang Xiaodong | Director | OPT+S | $223.50 | 41,760 | $9,333,272 | 0 |
| 2025-05-15 23:39 | 2025-05-13 | KNSA | Kiniksa Pharmaceuticals International, plc | Patel Sanj K | Director, Officer | OPT+S | $27.03 | 2,872 | $77,630 | 96,674 |
| 2025-05-16 00:08 | 2025-05-15 | TNXP | Tonix Pharmaceuticals Holding Corp. | LEDERMAN SETH | Director, Officer | BUY | $21.55 | 4,000 | $86,200 | 4,005 |
| 2025-05-15 23:43 | 2025-05-14 | NGNE | Neurogene Inc. | Cobb Stuart | Officer | SELL | $15.15 | 6,797 | $103,003 | 20,794 |
| 2025-05-15 23:18 | 2025-05-13 | ARQT | Arcutis Biotherapeutics Inc. | Heron Patrick J | Director | BUY | $13.76 | 8,674 | $119,352 | 14,974 |
| 2025-05-15 23:17 | 2025-05-13 | PHAT | Phathom Pharmaceuticals, Inc. | Topper James N | Director | BUY | $3.30 | 7,420 | $24,462 | 55,623 |
| 2025-05-16 04:37 | 2025-05-13 | MNKD | MANNKIND CORP | Thomson David | Officer | SELL | $4.68 | 32,179 | $150,598 | 772,427 |
| 2025-05-16 00:00 | 2025-05-13 | CPRX | CATALYST PHARMACEUTICALS, INC. | INGENITO GARY | Officer | OPT+S | $23.67 | 244,000 | $5,775,724 | 68,873 |
| 2025-05-15 23:02 | 2025-05-13 | EBS | Emergent BioSolutions Inc. | PAPA JOSEPH C | Director, Officer | BUY | $5.83 | 60,000 | $349,800 | 342,500 |
| 2025-05-15 23:09 | 2025-05-14 | OGN | Organon & Co. | COX CARRIE SMITH | Director | BUY | $8.07 | 12,469 | $100,591 | 12,469 |
| 2025-05-15 23:36 | 2025-05-13 | INSM | INSMED Inc | Smith Michael Alexander | Officer | SELL | $67.62 | 4,816 | $325,673 | 91,794 |
| 2025-05-15 23:34 | 2025-05-13 | INSM | INSMED Inc | Schaeffer Orlov S Nicole | Officer | SELL | $67.37 | 6,235 | $420,076 | 114,643 |
| 2025-05-15 23:33 | 2025-05-13 | INSM | INSMED Inc | Lewis William | Director, Officer | SELL | $66.73 | 21,213 | $1,415,573 | 312,973 |
| 2025-05-15 23:31 | 2025-05-13 | INSM | INSMED Inc | Flammer Martina M.D. | Officer | SELL | $67.43 | 10,152 | $684,571 | 90,013 |
| 2025-05-15 23:29 | 2025-05-13 | INSM | INSMED Inc | Bonstein Sara | Officer | SELL | $67.47 | 10,504 | $708,682 | 108,359 |
| 2025-05-15 23:26 | 2025-05-13 | INSM | INSMED Inc | Adsett Roger | Officer | SELL | $67.36 | 9,407 | $633,654 | 136,675 |
| 2025-05-16 01:51 | 2025-05-15 | CYTK | CYTOKINETICS INC | Bhanji Muna | Director | SELL | $29.73 | 1,454 | $43,227 | 23,510 |
| 2025-05-16 03:10 | 2025-05-14 | ANIP | Ani Pharmaceuticals Inc. | Mutz Christopher | Officer | SELL | $60.45 | 4,000 | $241,800 | 107,317 |
| 2025-05-15 00:58 | 2025-05-12 | APUS | Apimeds Pharmaceuticals US, Inc. | Koo Jakap | Director | BUY | $1.99 | 28,500 | $56,715 | 643,885 |
| 2025-05-15 00:52 | 2025-05-12 | APUS | Apimeds Pharmaceuticals US, Inc. | Inscobee Inc. | 10% owner | BUY | $4.00 | 500,000 | $2,000,000 | 1,984,616 |
| 2025-05-15 04:55 | 2025-05-12 | KTTA | Pasithea Therapeutics Corp. | Marques Tiago | Director, Officer | SELL | $0.83 | 960 | $792 | 40,001 |
| 2025-05-15 01:00 | 2025-05-12 | VTRS | Viatris Inc | Smith Scott Andrew | Director, Officer | BUY | $8.94 | 60,000 | $536,262 | 292,807 |
| 2025-05-14 23:36 | 2025-05-12 | OKUR | OnKure Therapeutics, Inc. | Cormorant Asset Management, LP | 10% owner | SELL | $1.99 | 24,300 | $48,236 | 1,813,439 |
| 2025-05-15 02:27 | 2025-05-13 | EOLS | Evolus, Inc. | Beaver Sandra | Officer | SELL | $10.02 | 6,494 | $65,070 | 167,089 |
| 2025-05-15 02:27 | 2025-05-12 | EOLS | Evolus, Inc. | MOATAZEDI DAVID | Director, Officer | SELL | $9.87 | 15,787 | $155,756 | 492,832 |
| 2025-05-14 21:06 | 2025-05-12 | PRGO | PERRIGO Co plc | Parker Geoffrey M. | Director | BUY | $27.10 | 3,500 | $94,850 | 23,762 |
| 2025-05-15 02:27 | 2025-05-12 | EOLS | Evolus, Inc. | Avelar Rui | Officer | SELL | $9.87 | 3,385 | $33,397 | 359,082 |
| 2025-05-14 23:56 | 2025-05-12 | HROW | HARROW, INC. | Opaleye Management Inc. | 10% owner | SELL | $26.13 | 15,000 | $391,904 | 125,000 |
| 2025-05-14 23:54 | 2025-03-24 | HROW | HARROW, INC. | Opaleye Management Inc. | 10% owner | SELL | $30.01 | 5,000 | $150,055 | 140,000 |
| 2025-05-15 01:08 | 2025-05-12 | HOWL | Werewolf Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | BUY | $0.91 | 536,426 | $487,182 | 6,237,482 |
| 2025-05-15 00:00 | 2025-05-12 | ALZN | Alzamend Neuro Inc. | AULT MILTON C III | Director, 10% owner | SELL | $5.06 | 1,224 | $6,196 | 1,843 |
| 2025-05-14 23:04 | 2025-05-12 | GYRE | GYRE THERAPEUTICS, INC. | Ma Songjiang | Director, Officer | SELL | $10.97 | 4,000 | $43,860 | 2,820,844 |
| 2025-05-15 00:51 | 2025-05-12 | CORT | CORCEPT THERAPEUTICS INC | Swisher Daniel N JR | Director | OPT+S | $72.06 | 2,200 | $158,526 | 0 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.